Hormone Therapy Considerations

Assessment and Initiation

• Determining menopausal status is critical for selecting the appropriate hormone therapy regimen, according to the Journal of Clinical Oncology 1
• The American College of Clinical Oncology recommends evaluating for contraindications, including history of breast cancer or other hormone-sensitive cancers, active liver disease, history of venous thromboembolism or stroke, antiphospholipid syndrome, and undiagnosed abnormal vaginal bleeding, as stated in Praxis Medical Insights 2

Hormone Therapy for Premenopausal Women

• For post-pubertal women with Premature Ovarian Insufficiency (POI), a customized approach based on individual needs and preferences is recommended by Blood Reviews 3, 4
• The Endocrine Society suggests that if no contraception is required, transdermal 17β-estradiol is the first-line treatment for women with POI, as per Blood Reviews 4
• Treatment options should consider the need for contraception, as stated in Blood Reviews 3, and the desire for withdrawal bleeding, also from Blood Reviews 4

Hormone Therapy for Postmenopausal Women

• For women with an intact uterus, the American College of Obstetricians and Gynecologists recommends always combining estrogen with a progestin to reduce endometrial cancer risk, as stated in Praxis Medical Insights 2
• The use of micronized progesterone (100-200 mg daily for 12-14 days every 28 days) is preferred due to its physiological and safe profile, according to Blood Reviews 3

Alternative Options for Vasomotor Symptoms

• If hormone therapy is contraindicated, consider low-dose paroxetine (7.5 mg daily) for vasomotor symptoms, as recommended by Praxis Medical Insights 5
• The Journal of Clinical Oncology suggests considering venlafaxine, gabapentin, or clonidine as alternatives, and notes that cognitive behavioral therapy may provide additional benefit 1, 5
• Important caution: Paroxetine and fluoxetine should not be offered to women taking tamoxifen as they inhibit conversion to active metabolites, as stated in the Journal of Clinical Oncology and Praxis Medical Insights 1, 5

Common Pitfalls to Avoid

• Initiating hormone therapy solely for prevention of chronic conditions rather than symptom management is a common pitfall, as stated in Praxis Medical Insights 2
• Using estrogen therapy without progestin in women with an intact uterus is also a pitfall to avoid, according to Praxis Medical Insights 2